Chemplast Sanmar denies acquisition of Symed Labs
Chemplast Sanmar Limited, a listed pharmaceutical and specialty chemicals manufacturer, formally denied via NSE intimation that it had entered into any definitive agreement to acquire Symed Labs Limited. The denial was filed under Regulation 30(11) of the SEBI Listing Obligations and Disclosure Requirements (LODR), 2015, which requires listed companies to immediately correct or clarify any material news that may be misleading. No transaction value, consideration structure, or conditions were disclosed, as the company categorically denied the transaction.
Why it mattersThe Regulation 30(11) denial establishes that no material agreement existed as at the filing date; counsel advising on any subsequent Chemplast–Symed transaction must establish independent due diligence and document that any future agreement is arm's length and material-event-gated, given the prior market denial.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives (Corporate Announcements) · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026